Group 2A: HER2+ Breast Cancer—Metastatic; Brain Metastasis



Thursday, June 9
2:00 pm – 3:30 pm Eastern Time (US/New York)



Mentor: Cathy Knowles

Cathy Knowles lives in Pensacola, Florida with her husband and two dogs. She received a diagnosis of de novo with metastasis in her liver in January of 2017. She is ER+HER2+ and still on her first line of treatment. Cathy retired in 2019 after spending most of her career as a research associate/lab manager in several basic biomedical research programs in institutional settings as well as academia. She is a lifelong learner and her involvement with GRASP is unique and inspiring.

Scientist: Evandro de Azambuja, M.D., Ph.D.

Evandro de Azambuja, M.D., Ph.D., is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium. Dr. de Azambuja earned his first PhD from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, in May 2007 and his second PhD from the Université Libre de Bruxelles (U.L.B) in December 2015.

His principal interest in oncology is breast cancer, especially in the adjuvant/neoadjuvant settings. He is deeply involved in the conduct of large phase III trials in breast cancer (some of them practice changing in breast cancer) such as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib), APHINITY (trastuzumab with or without pertuzumab), Alexandra (adjuvant atezolizumab in triple negative breast cancer) and – in the neoadjuvant setting – the LORELEI trial which tested the efficacy of PI3K inhibition in combination with endocrine therapy. He is also greatly engaged in studies concerning cancer toxicity of new drugs in oncology as well as in long-term follow-up of patients enrolled in clinical trials with focus in cardiotoxicity. Within the latter context, he was a co-author of guidelines on treatment-related cardiac toxicity by the European Society for Medical Oncology (ESMO) and the European Society of Cardiology (ESC). He was past chair of the survivorship of the Belgian Society of Medical Oncology (BSMO).

Twitter: @E_de_Azambuja